Niagen Bioscience
NAGE
46 hedge funds and large institutions have $13.6M invested in Niagen Bioscience in 2017 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 16 increasing their positions, 12 reducing their positions, and 9 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 12
1.15% more ownership
Funds ownership: 12.16% → 13.31% (+1.1%)
11% less capital invested
Capital invested by funds: $15.3M → $13.6M (-$1.69M)
12% less funds holding
Funds holding: 52 → 46 (-6)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.45M |
| 2 |
TCM
Tieton Capital Management
Yakima,
Washington
|
+$1.95M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$111K |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$87.2K |
| 5 |
Barclays
London,
United Kingdom
|
+$32K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$209K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$188K |
| 3 |
NSIM
North Star Investment Management
Chicago,
Illinois
|
-$170K |
| 4 |
Morgan Stanley
New York
|
-$129K |
| 5 |
Citigroup
New York
|
-$81.5K |
NAGE Hedge Fund Activity: Q1 2017 in Review
46 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q1 2017, worth a combined $13.6M — down 11% from $15.3M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of NAGE and 7 opened new positions — a net loss of 2 holders — while 12 trimmed existing stakes and 16 added.
The largest buyer was BlackRock, adding an estimated $3.45M. The largest seller was Millennium Management, cutting an estimated $209K.
- 46 institutional investors held Niagen Bioscience (NAGE) as of Q1 2017, down from 52 in Q4 2016.
- Funds reported $13.6M of Niagen Bioscience stock for Q1 2017, down 11% quarter-over-quarter.
- 7 funds opened new Niagen Bioscience positions in Q1 2017 and 9 closed out, a net change of -2 holders.
- The largest Niagen Bioscience buyer in Q1 2017 was BlackRock, an estimated $3.45M added.
- The largest Niagen Bioscience seller in Q1 2017 was Millennium Management, an estimated $209K sold.
Based on aggregated 13F filings for Q1 2017.